Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022
18 mars 2022 13h15 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea
17 mars 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 17, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation to Present at the 34th Annual ROTH Conference
09 mars 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation
11 févr. 2022 08h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
13 janv. 2022 07h00 HE
|
Journey Medical Corporation
Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition...
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
10 déc. 2021 08h00 HE
|
Journey Medical Corporation
Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10,...
Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference
07 déc. 2021 16h05 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Introduces Expanded Board of Directors
29 nov. 2021 08h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded...
Journey Medical Corporation Announces Closing of Initial Public Offering
16 nov. 2021 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Prices $35.2 Million Initial Public Offering
12 nov. 2021 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...